Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Lannett Company, Inc.    LCI

LANNETT COMPANY, INC.

(LCI)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Robbins Arroyo LLP: Shareholder Class Action Against Lannett Company (LCI) Survives Motion to Dismiss

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2019 | 07:48pm EDT

Shareholder rights law firm Robbins Arroyo LLP announces that Lannett Company (NYSE: LCI) may face damages caused by a pending securities lawsuit action lawsuit. Lannett develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States.

View this information on the law firm's Shareholder Rights Blog:
https://www.robbinsarroyo.com/lannett-company-may-19/

Shareholder Class Action Alleging Lannett Made Materially False and Misleading Statements Survives Motion to Dismiss

Investors filed a class action complaint against Lannett for alleged violations of the Securities Exchange Act of 1934. According to the complaint, since 2013, Lannett's business strategy has been to collusively enter into industry-wide anti-competitive agreements with other generic drug manufacturers. Extensive regulatory investigations revealed that Lannett was involved in an industry-wide conspiracy to fix prices and allocate territories for the sale of at least 18 different generic medications. Nevertheless, Lannett insiders misled investors by stating that price increases were the result of legitimate and competitive market forces contrary to their knowledge that the market was being driven by antitrust violations. The complaint further alleges that Lannett insiders misrepresented the scope of their investigations into potential antitrust violations and the likelihood that Lannett would be implicated in the broader price-fixing procecutions. Capitalizing on Lannett's artificially inflated stock prices, certain executives made nearly $10 million in insider sales. As a result of its price-fixing, Lannett is now defending itself against regulatory inquiries and investigations and private lawsuits alleging securities fraud, consumer deception, and violations of state and federal antitrust laws. On May 15, 2019, U.S. District Court Judge Wendy Beetlestone denied Lannett's motion to dismiss plaintiffs' complaint, paving the way for litigation to proceed.

Lannett Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Sign up for our FREE portfolio monitoring service, Stock Watch.

Attorney Advertising. Past results do not guarantee a similar outcome.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LANNETT COMPANY, INC.
04:18pLANNETT CO INC : Change in Directors or Principal Officers, Financial Statements..
AQ
04:10p(LCI) ALERT : Johnson Fistel, LLP Announces Investigation of Lannett Company, In..
PR
06:53aLANNETT : Appoints Melissa V. Rewolinski, PhD, To Board Of Directors
PR
05/21LANNETT CO INC : Other Events (form 8-K)
AQ
05/21LANNETT : Haeggquist & Eck Investigates Conspiracy to Fix Prices on Generic Drug..
BU
05/21LANNETT : Purchases Additional $30.5 Million Of Term A Loans
PR
05/17ROBBINS ARROYO LLP : Shareholder Class Action Against Lannett Company (LCI) Surv..
BU
05/17LANNETT : Begins Marketing Generic Adderall
AQ
05/16LANNETT : Begins Marketing Generic Adderall®
PR
05/13LANNETT Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedi..
PR
More news
Financials ($)
Sales 2019 640 M
EBIT 2019 176 M
Net income 2019 -76,8 M
Debt 2019 653 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 1,39x
EV / Sales 2020 1,69x
Capitalization 238 M
Chart LANNETT COMPANY, INC.
Duration : Period :
Lannett Company, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANNETT COMPANY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 8,88 $
Spread / Average Target 47%
EPS Revisions
Managers
NameTitle
Timothy C. Crew Chief Executive Officer & Director
Patrick G. LePore Chairman
John Abt Chief Operations & Quality Officer, Vice President
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Sector and Competitors
1st jan.Capitalization (M$)
LANNETT COMPANY, INC.21.98%238
JOHNSON & JOHNSON7.03%368 416
PFIZER-4.54%233 461
ROCHE HOLDING LTD.9.84%228 186
NOVARTIS13.31%210 460
MERCK AND COMPANY5.98%208 495